Many pancreatic tumors are like malignant fortresses, surrounded by a dense matrix of collagen and other tissue that shields them from immune cells and immunotherapies that have been effective in treating other cancers. Employing bacteria to infiltrate that cancerous fortification and deliver these drugs could aid treatment for pancreatic cancer, according to newly published findings from a team of University of Wisconsin–Madison researchers.
Sepsis is a condition in which the body responds improperly. More specifically, the infection causes the organs in the body to shut down. This is a serious illness which could lead to extremely low blood pressure or septic shock. In this case, permanent damage to the lungs, kidneys, liver, and other organs can occur. Unfortunately, if the damage is extensive enough, it could be fatal. Common symptoms associated with sepsis includes alteration of mental status, shallow breathing, sweating out of context, lightheadedness, chills, and other symptoms associated with infection or fever. Sepsis can lead to septic shock and raises the risk of death. Symptoms of septic shock include inability to stand, sleepiness, and extreme confusion. Interestingly, symptoms can vary between people, and it is important to monitor bodily changes to detect sepsis as early as possible. Bacterial, viral, or fungal infections can lead to sepsis including common infections such as pneumonia, urinary tract infections, and burns, among others. It is critical to see a doctor if you suspect you are not getting better or if your symptoms worsen. Early detection of sepsis can help improve survival rate and prevent permanent organ damage. Treatments include antibiotics, increased fluids, vasopressors to increase blood pressure, and steroids. Although scientists and physicians have worked to understand sepsis and how to treat it, other discoveries are yet to be made.
A recent study in Nature Immunology by Dr. Antoine Roquilly from Nantes University in France, demonstrated that patients that experienced sepsis build strong immune cells that aid in the prevention of tumor development. It was previously unknown how the immune landscape was shaped after a patient recovered from sepsis. Roquilly and his team wanted to understand the relationship between these exposed immune cells and the risk of developing cancer in the future.
Roquilly’s research team first analyzed big datasets that consisted of information from patients who survived sepsis. Researchers were able to determine the risk of cancer prevalence up to 10 years following the discharge from the hospital for sepsis patients. Interestingly, sepsis survivors had lower risk of developing cancer compared to those that did not have sepsis.
THE END OF ACADEMIA?
The pandemic and industrial action has caused massive upheaval in the education system in recent years, and many students feel short-changed.
Glioblastomas are an extremely aggressive type of brain tumour, which is why the news this week of a vaccine that has shown promise in fighting them is so exciting. And this comes right off the back of the announcement of another trial of the world’s first personalised mRNA vaccine for melanoma, a kind of skin cancer. Ian Sample talks to Prof Alan Melcher of the Institute of Cancer Research about how these vaccines work and whether they could one day be used to target cancer before it is even detectable on scans.
Study found that exoglycosidases from Akkermansia muciniphila effectively target blood group antigens, potentially converting A and B blood types to ABO-universal blood.
For the first time, chemists in the University of Minnesota Twin Cities College of Science and Engineering have created a highly reactive chemical compound that has eluded scientists for more than 120 years. The discovery could lead to new drug treatments, safer agricultural products, and better electronics. The study is published in Science.
A NEW mRNA cancer vaccine can reprogram the immune system to attack tumours within 48 hours, a study shows.
The first-ever human clinical trial of four adult patients showed the jab helps fight against aggressive and deadly brain tumours.
A QUT-led team of international researchers has made a breakthrough in the development of a type of battery that is much safer and cheaper than the batteries currently charging our smart devices.
The research, published in the prestigious Journal of the American Chemical Society, has demonstrated a way of improving the voltage of aqueous zinc-ion batteries, which are a type of rechargeable battery which have a water-based electrolyte.
QUT researchers involved in the study are Professor Ziqi Sun, Associate Professor Dongchen Qi, and Fan Zhang from the School of Chemistry and Physics, Professor Ting Liao and Professor Cheng Yan from the School of Mechanical, Medical and Process Engineering and Dr Aaron Micallef from the Central Analytical Research Facility.
From the brain to the bowels, a division of labor between resident tissue lmacrophages keeps organs healthy.
Learn more in a new Science Immunology Review: #DayOfImmunology
